Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Cash from Operations (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Cash from Operations for 6 consecutive years, with 32002000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 16.74% to 32002000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 135319000.0 through Dec 2025, down 22.1% year-over-year, with the annual reading at 135319000.0 for FY2025, 22.1% down from the prior year.
  • Cash from Operations for Q4 2025 was 32002000.0 at TScan Therapeutics, up from 32464000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 8017000.0 in Q3 2023, with the low at 37586000.0 in Q1 2025.
  • Average Cash from Operations over 5 years is 21133950.0, with a median of 22804500.0 recorded in 2023.
  • The sharpest move saw Cash from Operations surged 147.15% in 2023, then tumbled 448.24% in 2024.
  • Over 5 years, Cash from Operations stood at 14380000.0 in 2021, then decreased by 11.34% to 16010000.0 in 2022, then plummeted by 48.44% to 23766000.0 in 2023, then fell by 15.34% to 27412000.0 in 2024, then fell by 16.74% to 32002000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 32002000.0, 32464000.0, and 33267000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.